Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 587 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Adjuvant Radiotherapy Clear all
Completed Not applicable Interventional Results available

Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT

NCT01664091
View directory record Official record
Conditions
Breast Cancer
Interventions
post-mastectomy radiation therapy (PMRT), tissue expander (TE), acellular dermal matrix (ADM)
Radiation · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Sep 30, 2026, 5:38 AM EDT
Recruiting Phase 1 Interventional

CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

NCT06305910
View directory record Official record
Conditions
Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma
Interventions
Treatment with CD200AR-L
Drug
Lead sponsor
OX2 Therapeutics
Industry
Eligibility
2 Years to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 30, 2026, 5:38 AM EDT
Recruiting Phase 1 Interventional

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

NCT06130995
View directory record Official record
Conditions
Androgen Deprivation Therapy, Locally Advanced Prostate Cancer
Interventions
Relugolix and Enzalutamide
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 30, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

Low Dose Radiation Therapy for Glioblastoma Multiforme

NCT01466686
View directory record Official record
Conditions
High Grade Glioma
Interventions
Low Dose Fractionated Radiation Therapy (LDFRT), Temozolomide
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Sep 30, 2026, 5:38 AM EDT
Terminated Not applicable Interventional

Adjuvant Radiation for High Risk Bladder Cancer

NCT01954173
View directory record Official record
Conditions
Bladder Cancer, Squamous Cell Carcinoma of the Bladder, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Interventions
3D conformal radiation therapy
Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 30, 2026, 5:38 AM EDT
Not listed Phase 1 Interventional

Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer

NCT04052412
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
18F-AraG
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Sep 30, 2026, 5:38 AM EDT
Active, not recruiting Phase 2 Interventional

Shortened Course Adjuvant Radiotherapy Following TORS

NCT05714657
View directory record Official record
Conditions
HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Interventions
Shortened Course Adjuvant Radiotherapy Following TORS
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Lancaster, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 30, 2026, 5:38 AM EDT
Completed Phase 1 Interventional

Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma

NCT00822848
View directory record Official record
Conditions
Sarcoma
Interventions
epirubicin hydrochloride, ifosfamide, sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, hypofractionated radiation therapy
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
15 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Sep 30, 2026, 5:38 AM EDT
Completed Phase 1 Interventional

Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC

NCT04042935
View directory record Official record
Conditions
HNSCC
Interventions
Alpha Lipoic Acid
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 30, 2026, 5:38 AM EDT
Withdrawn Not applicable Interventional

Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer

NCT07136493
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, HER2-Positive Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Electronic Health Record Review, Survey Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Goodyear, Arizona • Duarte, California • Irvine, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 30, 2026, 5:38 AM EDT
Not listed Phase 2 Interventional

Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas

NCT00492687
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carboplatin, tamoxifen citrate, temozolomide, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
San Diego Pacific Oncology & Hematology Associates
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Sep 30, 2026, 5:38 AM EDT
Not listed Phase 2 Interventional

MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)

NCT04874506
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
MBM-02
Drug
Lead sponsor
Matrix Biomed, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 30, 2026, 5:38 AM EDT
Completed Phase 3 Interventional

Immunotherapy Study for Surgically Resected Pancreatic Cancer

NCT01072981
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
HyperAcute-Pancreas Immunotherapy, Gemcitabine, 5FU Chemoradiation
Biological · Drug · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Sep 30, 2026, 5:38 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome

NCT03665077
View directory record Official record
Conditions
Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS), Breast Cancer
Interventions
Initial blood draw, Initial SWE ultrasound, Blood draw at three months, Blood draw at six months, SWE ultrasound at six months
Diagnostic Test
Lead sponsor
University of Arizona
Other
Eligibility
21 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 30, 2026, 5:38 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Selpercatinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Stockton, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 30, 2026, 5:38 AM EDT
Not listed Phase 1 Interventional

CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

NCT00768911
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
CT-322, Temozolomide, Radiation Therapy
Drug · Procedure
Lead sponsor
Adnexus, A Bristol-Myers Squibb R&D Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Little Rock, Arkansas • Chicago, Illinois • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2010 · Synced Sep 30, 2026, 5:38 AM EDT
Completed Phase 2 Interventional

A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer

NCT06145412
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Xevinapan, Cisplatin, External beam
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 30, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages

NCT03274414
View directory record Official record
Conditions
Paranasal Sinus Cancer, Nasal Cavity Tumor, Nasal Cavity Adenocarcinoma
Interventions
Cisplatin, Adjuvant Proton Radiotherapy, Endoscopic Resection, cisplatin and etoposide
Drug · Radiation · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Sep 30, 2026, 5:38 AM EDT
Completed Phase 3 Interventional Results available

Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma

NCT00346164
View directory record Official record
Conditions
Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma, Adult Malignant Hemangiopericytoma, Adult Malignant Mesenchymoma, Adult Neurofibrosarcoma, Adult Synovial Sarcoma, Childhood Alveolar Soft-part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Mesenchymoma, Childhood Neurofibrosarcoma, Childhood Synovial Sarcoma, Dermatofibrosarcoma Protuberans, Metastatic Childhood Soft Tissue Sarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery, 3-dimensional conformal radiation therapy, ifosfamide
Drug · Other · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 133 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 30, 2026, 5:38 AM EDT
Completed Not applicable Interventional

Proton Radiation for Resectable Carcinoma of the Pancreas

NCT00763516
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Proton radiation and chemotherapy
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Sep 30, 2026, 5:38 AM EDT
Active, not recruiting Phase 2 Interventional

A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity

NCT03092323
View directory record Official record
Conditions
Soft Tissue Sarcoma of the Extremity
Interventions
Pembrolizumab
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
12 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Jacksonville, Florida • Iowa City, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Sep 30, 2026, 5:38 AM EDT
Completed Not applicable Interventional

Acute Radiation Dermatitis After Adjuvant Radiotherapy for Breast Cancer Patients With the Use of Silver-Plated Technology

NCT06831084
View directory record Official record
Conditions
Radiation Dermatitis Acute
Interventions
Silver plated technology (SPT) dressing
Device
Lead sponsor
Parul Barry
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 30, 2026, 5:38 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

NCT03969004
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
Cemiplimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
40
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Sep 30, 2026, 5:38 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

International PPB/DICER1 Registry

NCT03382158
View directory record Official record
Conditions
Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor, DICER1 Syndrome, Cystic Nephroma, Wilms Tumor, Pineoblastoma, Renal Sarcoma, Nodular Hyperplasia of Thyroid, Nasal Chondromesenchymal Hamartoma, Ciliary Body Medulloepithelioma, Neuroblastoma, Pituitary Cancer, Embryonal Rhabdomyosarcoma, Ovarian Sarcoma, Gynandroblastoma, Thyroid Carcinoma, Embryonal Rhabdomyosarcoma of Vagina (Diagnosis), Embryonal Rhabdomyosarcoma of Uterus (Diagnosis), Embryonal Rhabdomyosarcoma of Cervix
Interventions
Not listed
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
0 Minutes to 100 Years
Enrollment
3,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2035
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 30, 2026, 5:38 AM EDT